Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GNYS SEC Suspension:
http://www.sec.gov/litigation/suspensions/2014/34-72092.pdf
Order:
http://www.sec.gov/litigation/suspensions/2014/34-72092-o.pdf
Admin Proceeding:
http://www.sec.gov/litigation/admin/2014/34-72093.pdf
that is interesting..thats probably why..looks like this has been in the works for sometime. Heres to this company finally waking soon!!!! Surely we been patient lol
The individual dates everything went down is interesting... been in the works for a while. 'may' explain why the ceo and cfo wouldn't return my calls....
GM DB!Hmmm we shall see..fingers crossed this CEO gets it goin!!sheesh
8k, 'maybe' something finally happens under new ceo? OR are they fleeing a sinking ship??
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act
April 19, 2012
Date of Report
(Date of earliest event reported)
GeNOsys, INC.
(Exact name of registrant as specified in its charter)
Utah
000-49817
87-0671592
(State or Other Jurisdiction of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
86 N. University Ave., Suite 400
Provo, Utah 84601
(Address of Principal Executive Offices)
(801) 623-4751
(Registrant's Telephone Number)
N/A
(Former Name or Former Address if changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see general instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14-a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 5.02
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On April 19, 2012, Keith Merrell resigned as a director.
On February 22, 2013, the Board of Directors accepted the resignation of Dale Fillmore as Chairman of the Board, Chief Executive Officer and President. On the same day, the Board appointed John W. R. Miller as Chairman of the Board, Chief Executive Officer and President.
On May 28, 2013, Mr. Fillmore resigned as a director.
On May 31, 2013, Mr. Merrell resigned as Chief Financial Officer.
There were no disagreements with any of these individuals and the Company.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
GeNOsys, INC.
Date: June 5, 2013
By/s/John W. R. Miller
Chief Executive Officer, President and
Chairman of the Board
good finds..maybe they have some press soon now
http://www.freepatentsonline.com/8434475.html
excerpt:
"
Title:Nitric oxide reactor and distributor apparatus and method Document Type and Number:United States Patent 8434475
Abstract:A reaction and distribution system may include a distributor securable near or in a path correspond to a breathing passage such as the nostrils or the mouth of a user for delivering nitric oxide therapy thereto. The distributor may contain an internal reactor for creating the nitric oxide from reactants. Alternative embodiments may rely on a line delivering nitric oxide to the distributor from a remote generator such as a cannister carried in a pocket or placed/at the bedside of a user.
Inventors:Miller, Randy J. (Orem, UT, US)
Jones, Christie M. (Chula Vista, CA, US)
Application Number:12/361151
Publication Date:05/07/2013
Filing Date:01/28/2009
View Patent Images:Download PDF 8434475 PDF help Export Citation:Click for automatic bibliography generation Assignee:Genosys, Inc. (Provo, UT, US)
Primary Class:128/203.12 Other Classes:128/202.26, 128/203.25, 424/718 International Classes:A61M15/00; A61M16/00 Field of Search:424/718, 128/202.26, 128/203.12, 128/203.25
"
.
.
.
"
Claims:What is claimed and desired to be secured by United States Letters Patent is:
1. A method for nitric oxide therapy comprising: providing a distributor placed to deliver nitric oxide to a breathing stream of a user; providing a reactor producing nitric oxide wherein the reactor is portable with the user and sized to contain reactants sufficient to provide a single therapy session dose of nitric oxide and is connected in fluid communication with the distributor, wherein the reactor contains at least two reactants comprising a first reactant contained in a first chamber and a second reactant contained in a second chamber, the reactants being separated by a chamber wall that is ruptured to promote mixing; initiating production of nitric oxide by mixing reactants in the reactor; separating the nitric oxide from reactants and other species resulting from the reaction by filtering the nitric oxide through a porous molecular sieve that contacts one of the first or second reactants; and delivering the nitric oxide to the distributor.
2. The method of claim 1, further comprising providing a securement to secure the distributor on the person of the user after providing the reactor.
3. The method of claim 2, wherein the distributor is positioned and secured to deliver the nitric oxide directly into the nostrils of the user.
4. The method of claim 2, wherein the securement includes an adhesive strip securing the distributor to the user.
5. The method of claim 1, wherein the concentration of nitric oxide delivered from the distributor to the user is from about one thousand parts per million to about ten thousand parts per million of nitric oxide.
6. The method of claim 1, wherein at least a portion of the second chamber is contained within the first chamber.
7. The method of claim 1, wherein the reactor is non-toxic after use.
8. The method of claim 1, wherein the first reactant is a composition of nitrogen and the second reactant is a moderate acid.
9. The method of claim 8, wherein the first reactant comprises at least one composition of nitrogen selected from the group consisting of potassium nitrite and sodium nitrite and the second reactant comprises at least two moderate acids selected from the group consisting of citric acid, ascorbic acid, and acetic acid.
10. A method for nitric oxide therapy comprising: providing a distributor placed to deliver nitric oxide directly into the nostrils of a user; providing a reactor comprising at least a first chamber and a second chamber wherein the first chamber contains at least one composition of nitrogen selected from the group consisting of potassium nitrite and sodium nitrite and the second chamber contains at least two moderate acids selected from the group consisting of citric acid, ascorbic acid, and acetic acid and the first and second chambers separated by a rupturable chamber wall; the providing the reactor further comprising providing the reactor sized to be portable and connected in fluid communication with the distributor; the providing a reactor further comprising providing a single therapy session dose of nitric oxide to the user; initiating production of nitric oxide by mixing the reactants in the first and second chambers; separating the nitric oxide from the reactants and other species resulting from the reaction by filtering the nitric oxide through a porous molecular sieve that contacts one of the first or second reactants; and delivering through the distributor to the user a concentration of nitric oxide from about one thousand parts per million to about ten thousand parts per million of nitric oxide.
Description:BACKGROUND
1. The Field of the Invention
This invention relates to treatments providing nitric oxide as a vasodilator, and, more particularly, to generation and delivery of gaseous nitric oxide for inhaling.
2. Background
The discovery of the nitric oxide effect in live tissues garnered a Nobel prize. Much of the work in determining the mechanisms for implementing and the effects of nitric oxide administration are reported in literature including papers, advertising, catalogs, and patents. Much of the work deals with introduction of substances that provide a nitric oxide effect in the body. Still other applications may involve topical preparations introducing nitric oxide. Still other applications rely on bottled nitric oxide gas. Introduction of nitric oxide to the human body has traditionally been expensive.
The therapies, compositions, and preparations are sufficiently expensive to inhibit more widespread use of such therapies. What is needed is a comparatively inexpensive mechanism for introducing nitric oxide in a single dosage over a predetermined period of time. Also, what is needed is a simple introduction method for providing nitric oxide suitable for inhaling.
BRIEF SUMMARY OF THE INVENTION
In accordance with the foregoing, certain embodiments of an apparatus and method in accordance with the invention provide a reactive kit having two compounds, typically disposed in carriers. The two compounds are separated from one another prior to administration. In order to administer the nitric oxide, reactants are mixed in with one another beginning a reaction releasing nitric oxide.
An adhesive member may secure a distributor to a mask or directly to the skin of a user proximate the nose. Nitric oxide may thus be introduced into the breathing air of a subject. Nitric oxide amounts may be engineered to deliver at a comparatively low rate in the hundreds of parts per million, or in a therapeutically effective amount on the order of thousands of parts per million. For example, sufficient nitric oxide may be presented through nasal inhalation to provide approximately five thousand parts per million in breathing air. This may be diluted due to additional bypass breathing through nasal inhalation or through oral inhalation.
One embodiment of an apparatus and method in accordance with the present invention may rely on a small reactor feeding a distributor secured to an upper lip of a user. A diffuser may secure to one side of an adhesive strip, while a treated backing paper, easily removable, may be secured to the opposite side of the adhesive strip. A reactor may be sized to contain reactants as solids, liquids, or gels compounded to have an appropriate moisture content to support reaction of reactants. A second reactant composition in a carrier may be sealed or otherwise separated from the first reactant composition. For example, the two reactants may be contained in separate volumes. Alternatively, reactive solids may simply be appropriately combined dry, or even separated by an intervening layer, such as a film, paper, or the like. The reaction may begin upon introduction of a liquid transport material to support ionic or other chemical reactions. The reactants held in separate, sealed volumes may be opened and mixed or otherwise placed in contact with one another to permit combination of the ingredients needed to form nitric oxide. In one embodiment, the reactants may include an acid, such as ascorbic acid, citric acid, or the like as a hydrogen donor. The other reactant may include potassium nitrite, sodium nitrite or the like.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing features of the present invention will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that these drawings depict only typical embodiments of the invention and are, therefore, not to be considered limiting of its scope, the invention will be described with additional specificity and detail through use of the accompanying drawings in which:
FIG. 1 is a perspective view of one embodiment of a system for generating and delivering nitric oxide in accordance with the invention;
FIG. 2 is an exploded view of alternative, cross-sectional, end views of the distributor of FIG. 1;
FIG. 3 is a perspective view of various alternative embodiments for a reaction chamber for the apparatus of FIG. 1;
FIG. 4 is a partially cut-away, perspective view of one embodiment of a reactor for use in the apparatus of FIGS. 1-3; and
FIG. 5 is a schematic block diagram of one embodiment of a method in accordance with the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It will be readily understood that the components of the present invention, as generally described and illustrated in the drawings herein, could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of the embodiments of the system and method of the present invention, as represented in the drawings, is not intended to limit the scope of the invention, as claimed, but is merely representative of various embodiments of the invention. The illustrated embodiments of the invention will be best understood by reference to the drawings, wherein like parts are designated by like numerals throughout.
Referring to FIG. 1, an apparatus 10 in accordance with the invention may include a vessel 12 or distributor 12. The distributor 12 may be configured to be flexible or may be pre-formed to fit the anatomy of a user. Typically, the distributor 12 will be placed on the upper lip of a user to provide the outputs 14 (e.g., output ports 14, or simply ports 14) access to the nostrils of a user during breathing. Each of the outputs 14 has an opening 15 for delivering nitric oxide directly into the nostrils of a user. Typically, sufficient clearance provides a bypass for air in addition to the nitric oxide from the distributor 12.
In certain embodiments of an apparatus in accordance with the invention, a distributor 12 may include a port 16 to operate as an input 16 for receiving nitric oxide from another source. For example, the port 16 may have an opening 17 for receiving from a line 18 a supply of nitric oxide.
In the illustrated embodiment, a reactor 20 provides a supply of nitric oxide to the distributor 12. As illustrated, one end 22 of a line 18 may connect to the input port 16 of the distributor 12. The opposite end 24 of the line 18 connects to the reactor 20. The opening 26 of the line 18 provides a lumina 26 value or passage 26 for passing the nitric oxide gas from the opening 28 of the fitting 30 on the reservoir 20.
In certain embodiments, the reactor 20 may be manufactured in a single-dose size. Accordingly, the distributor may be reused or disposed of. The reactor 20 may typically be disposed of after a single use. Circumferential hoop stresses are not high. Accordingly, the distributor 12, the line 18, and the reactor 20 may all be fabricated from comparatively lightweight and inexpensive materials such as plastic. Parts may be cast, molded, vacuum formed, assembled from film, or the like.
Referring to FIG. 2, the distributor 12 may be configured in various cross-sectional shapes. For example, the distributor 12 may typically have a principal wall 32 enclosing a chamber 34 or volume 34 containing the necessary materials for therapy. In certain embodiments, the chamber 34 may simply act as a manifold or distributor channel conducting nitric oxide gas. In other embodiments, the chamber 34 may completely enclose the reaction constituents and structures. Thus, the distributor 12 may serve as both a distributor 12 and reactor 20 in a single, integrated apparatus 10.
In various embodiments, the chamber 34 may include a vessel 36 inside or completely enclosed within the wall 32 and chamber 34 of the distributor 12. The internal vessel 36 may have a wall 38 that is permeable or impermeable. In certain embodiments, the vessel 36 may have a wall 38 formed of glass to maintain the vessel 36 sealed from the contents of the chamber 34. Accordingly, upon fracture of the wall 38, the contents of the vessel 36 may be spilled into the chamber 34 to mix with other reactants.
In certain embodiments, the chamber 40 formed by the wall 38 of the vessel 36 may contain a reactant. In other embodiments, the chamber 40 may simply contain a liquid. In yet other embodiments, the chamber 40 may contain dry ingredients that will become exposed to liquid from the chamber 34 upon fracture of the wall 38 and exposure of the chamber 40 to the contents of the chamber 34. All the foregoing roles can likewise be traded or reversed.
As can be seen, reactants may be separated to render them inactive. The reactants may later be combined to render them active and initiate a reaction. Likewise, the reactants may be maintained in proximity to one another in the chamber 34, the chamber 30, or both, or one may be maintained in a chamber 30, 34 dry and another wet. However, once both reactants are present in the presence of a liquid (e.g., transport fluid) in the opposite chamber 34, 30, the reaction to release nitric oxide may begin.
Any of the embodiments of FIG. 2 may be provided with an adhesive strip 42. One function of the adhesive strip is to secure the distributor 12 proximate the nostrils of a user in order that the distributor 12 may deliver nitric oxide through the openings 15 of the output ports 14. For clarity, the adhesive strip 42 has not been illustrated in every embodiment, although it may. Nevertheless, each of the embodiments may be provided with an adhesive strip 42. Meanwhile, any of the distributors 12 may be secured by some other method.
For example, the distributor 12 may be positioned within a mask covering the nose, the mouth, or both. Likewise, the distributor may be positioned by an air inlet to such a mask. In other embodiments, the distributor 12 may be positioned directly near the mouth, nostrils, or both. Accordingly, the output ports 14 may be shaped to accommodate the positioning thereof for delivery of nitric oxide to the breathing air stream of a subject.
In certain embodiments, an additional volume 48 may be separated within the chamber 34. For example, a layer 50 or wall 50 may seal the reactants away from one another. The wall 50 may be formed of a film, such as a molecular sieve. Such molecular sieves are available from suppliers and may be formed of various materials. One film produced under the trademark Nafion™ operates as a molecular sieve.
The value of a molecular sieve is that it is configured to have a pore size that will not permit passage of a compound of nitrogen having more than a single oxygen. Accordingly, only nitric oxide may pass through the molecular sieve. The molecular sieve, thus restrains the reactant liquids, any particulate matter, and all constituents larger than the nitric oxide molecule. Thus, the nitric oxide molecule may pass through the wall 50 and exit the chamber 34 through the output ports 14.
In yet other embodiments, the basic chamber 34 may be separated away from an additional chamber 48 or volume 48 by a seal 50 or wall 50. Meanwhile, the main chamber 34 may be further subdivided to create an additional volume 52 separated by a wall 54 or seal 54. In the illustrated embodiment, a volume of a first reactant in the chamber 48 is separated entirely from a volume of a second reactant in a chamber 52. Meanwhile, the remaining volume of the chamber 34 may be left as air space to receive the reactant gas passing through the molecular sieve of the layer 50.
Referring to FIG. 2, embodiment A is configured simply as a distributor 12 in which the chamber 34 enclosed by the wall 32 merely passes the nitric oxide for distribution to the output ports 14. Meanwhile, an adhesive layer 42 is bonded to the wall 32 and may be secured to the skin of a user upon removal of a layer 44 or cover 44 protecting the adhesive properties of the layer 42 from their environment during handling.
Embodiment B of FIG. 2 includes an additional chamber 40 separated by a wall 36. In this embodiments, one reactant may occupy the principal chamber 34, while a second reactant occupies the chamber 40 within the wall 36. If the wall 36 is formed of glass, then bending the distributor 12 may fracture the wall 36, exposing the reactants in the chamber 34 to the reactants in the chamber 40. Accordingly, the relative sizes of the chambers 34, 40 may be configured according to the necessary and appropriate quantities of the reactants contained therein, respectively.
The reactants in the chambers 34, 40 may be dry, wet, or one may be dry and one may be wet. Likewise, one chamber 34, 40 may contain both reactive ingredients mixed together but completely dry, while the other chamber 40, 34 contains a liquid capable of acting as a transport medium and thus activating the reaction between the dry ingredients.
Substantially all the illustrated embodiments for a reactor 20 or for a distributor 12 may benefit, as appropriate, from one of the foregoing configurations of dry, wet, or wet and dry ingredients, or dry ingredients and a wet transport material 12.
Embodiment C provides for a distributor 12 having one volume 48 enclosed by a molecular sieve layer 50. Meanwhile, a wall 36 encloses another chamber 40 containing another reactant. In this embodiment, the remainder of the volume of the chamber 34 outside the wall 50 of the molecular sieve is available as free space. Meanwhile, all reactants are contained within the molecular sieve layer 50.
A fracture of the wall 36 may release the reactants from the chambers 40, 48 to mix with one another and react. Meanwhile, the molecular sieve layer 50 contains all the reactants, as well as species of reaction that may be other than nitric oxide. Typically, nitric oxide is the principal output of the proposed reactants. Nevertheless, when exposed to the reaction process too long or when provided with outside oxygen, nitric oxide may become a more oxygenated reactant of nitrogen.
Embodiment D illustrates a more easily bendable shape, that may be more comfortable and more practical for forming about the upper lip of a user. For example, in any illustrated embodiment, any of the materials used to form the wall 32 of the chamber 34 may be comparatively rigid, moderately flexible such as a soft plastic or elastomer, or very flexible such as the materials used to form a toothpaste tube or other collapsible tube for containing a paste or liquid. Accordingly, the distributor 12 may be formed to fit the lip a user. Internal materials such as a wire imbedded in part of the wall 32 may facilitate bending the distributor 12 to a specific and permanent shape. Meanwhile, the adhesive strip 42 may secure a comparatively weak and soft material to the lip of a user and thus maintain the desired shape.
In embodiment D, the molecular sieve layer 50 may be a flexible film that provides additional space in the chamber 34 as gas accumulation space, while still containing the volume 48 of one reactant. In the illustrated embodiment, the chamber 40 is maintained within the wall 38 of a vessel 36. If the vessel 36 has a rigid wall 38, such as one formed of glass, a simple bending of the distributor 12 may permit mixing of the reactants in the chambers 40, 48 and discharge of the nitric oxide reactant through the wall 50 to accumulate in the remaining dry portion of the chamber 34 for ultimate discharge through the output ports 14.
Embodiment E provides a molecular sieve layer 50 permanently disposed across the chamber 34 separating a portion of the chamber 34 from a cavity 48 or volume 48 containing a reactant. Thus, a portion of the chamber 34 remains dry, while a portion is separated off as the volume 48 for containing a reactant. In this embodiment, the volume 40 is likewise contained by a wall 38 as a separate vessel 36 containing one of the reactants. Typical reactants are moderate acids such as citric acid, ascorbic acid, acetic acid, or the like. Meanwhile, typical reactants may involve compositions of nitrogen such as potassium nitrite, sodium nitrite, or the like. Reactants may be disposed as granules, powders, liquids in solution, solutions gelled to thixotropic consistency, or the like.
Embodiment F illustrates a distributor 12 that contains no reactants and does not act as a reactor 20 or reactant chamber 34. Rather, the chamber 34 of embodiment F is simply an empty cavity for distributing nitric oxide to the output ports 14.
Embodiment G may actually be configured in various shapes. However, as a manufacturing matter, alignment, assembly, and the like may be best served by more linear envelopes rather than curved ones. Nevertheless, the arrangement of embodiment G may actually be imposed on other shapes. In this embodiment, the chamber 34 may be separated by a molecular sieve layer 50 from a chamber 48 containing one reactant. Meanwhile, another seal 54 or wall 54 may separate the ingredients in the chamber 48 from the volume 52 or chamber 52 containing the second ingredient.
The entire reaction is contained within the wall 32, but the individual wall 50 acts a molecular sieve and will not be ruptured. By contrast, in order to initiate the reaction, the wall 54 may be compromised by perforating, fracture, rupture, tearing, cutting, or the like. Meanwhile, the remainder of the chamber 34 provides head space for the gas to accumulate for discharge through the output ports 14.
Referring to FIG. 3, a reactor 20 in the apparatus 10 may be configured in any suitable shape. Circular cross-sections tend to provide an equalization of hoop stresses. However, the reaction of materials contemplated for an apparatus 10 in accordance with the invention need not operate at an elevated pressure. Typically, the reaction may occur at about ambient conditions.
In embodiment A of FIG. 3, the reactor 20 may be configured as a rounded, yet somewhat flattened device having an aspect ration of width to thickness that is substantially larger than unity. Thus the width is more than the thickness, and in the illustrated embodiment is several times the thickness. Meanwhile, the aspect ratio of height to width may be selected according to space available in a convenient location for holding the reactor 20. For example, embodiment D may be a suitable configuration for setting on a table top. By contrast, embodiment A may be better suited for slipping into a shirt pocket, jacket pocket, or the like for portability. Meanwhile, the reactor 20 of embodiment C may be suitable for holding in a jacket pocket, or sitting on a night stand beside a bed or other flat surface.
Referring to FIG. 4, any of the reactors 20 of FIG. 3 may be configured to contain any or all of the chambers of FIG. 2. The reactor 20 may enclose various individual volumes. For example, in the illustrated embodiment, a volume 58 is enclosed within the wall 56 of the reactor 20. The volume 58 is bounded below by a layer 60 or sieve layer 60.
Optionally, a region of expansion space 62 may exist above a closure layer 64. The layer 64 initially forms a retainer or seal 64 to contain the volume 66 of a first reactant. The first reactant volume 66 is separated from a volume 68 containing the second reactant by a seal 70 that may be ruptured or otherwise compromised to initiate a reaction.
The closure layer 64 may be permeable. Alternatively it may be sealed impervious, to be breached in preparation for initiating the reaction in the reactor 20. It may be burst or otherwise opened or by the reaction.
In one embodiment, the layers 64, 70 may be formed of a polymer film, wax, or the like capable of maintaining the volumes 66, 68 separated from one another with their reactants. A mechanism such as a plunger, perforator, mixer, spatula, or other apparatus extending through the wall 56 may serve to break, rupture, tear, cut, or otherwise compromise the layer 70. Likewise, the layer 64 may be so opened and compromised in order to make the expansion space 62 available to the reactants.
The reactants in the volumes 66, 68 may be solid, liquid, one of each, or some other combination. For example, an additional layer, possibly even including the volume 62, may contain a liquid to provide a transport fluid for dry reactants in the volume surface 66, 68.
By whatever mechanism, the layers 64, 70 may be opened to expose the volumes 66, 68 with their reactant contents to one another in order to activate the reactor 20 and begin the chemical reaction to produce nitric oxide. Nitric oxide passes through the molecular sieve layer 60, which may be optional, but is useful in maintaining the purity of nitric oxide. The molecular sieve 60 or the layer 60 may include not only a molecular sieve, such as a film or solid layer, but may also include any other barrier materials suitable to maintain reactants outside of the collection volume 58 collecting the nitric oxide.
Ultimately, the nitric oxide in the volume 58 is passed through the fitting 30 into a line 18 for delivery into a distributor 12. Notwithstanding the illustrated embodiment of FIG. 4, any suitable shape may be used for the cross-section of the reactor 20. Accordingly, the reactor of FIG. 4 may actually be configured according to the relations, shapes, or both illustrated in any of the alternative embodiments illustrated in FIGS. 1-3.
In one alternative embodiment, the wall 56 may be highly flexible. Moreover, shape may be selected having an aspect ration of length to width that is comparatively larger than unity. The ratio of width to thickness may also be selected to be substantially larger than unity. Accordingly, the reactor 20 may be configured as a comparatively long, narrow tube, of a comparatively smaller thickness. Accordingly, the reactor 20 may be rolled up like a toothpaste tube or kneaded in order to rupture the seal layers 64, 70 and to mix the reactants in the volumes 66, 68.
If the volumes 66, 68 are filled with solutions, for example, reactants disposed in a solute liquid, or freely flowing gel, then mixing may readily occur. In other embodiments, diffusion alone may control the migration of reactant species between the volumes 66, 68. Thus, sealing layers 64, 70 may be formed, dividing the chambers or volumes 66, 68 containing reactants, which may then be extruded, mixed, drawn, flown, stirred, or otherwise introduced to one another to increase the available species participating in the reaction.
Referring to FIG. 5, one embodiment of an apparatus and method in accordance with the invention may rely on a series of process steps constituting a method 80 or process 80. For example, providing 82 a distributor 12 may involve any one or more of the required tasks of identifying materials, selecting a shape, selecting a cross-sectional profile and area, selecting aspect ratios of length to width to thickness, and determining the structural and mechanical characteristics for such a distributor 12. Accordingly, providing a distributor 12 may involve design, engineering, manufacture and acquisition of such a device.
Providing 80 a reactor may involve selection of materials, selection profile and of cross-sectional area, engineering, design, fabrication, acquisition, purchase, or the like of a reactor 20 in accordance with the discussion hereinabove.
Providing reactants 86 may include selection of reacting species, selecting a configuration, such as granules, powder, liquid, a solution, or the like. Likewise, the particular configuration of a solidous configuration of reactants may involve selecting a sieve size for the particles. This site can affect chemical reaction rates. Thus, selecting or otherwise providing 86 reactants for the reactor 20 may involve consideration of any or all aspects of chemistry, reaction kinetics, engineering, design, fabrication, purchase or other acquisition, delivery, assembly, or the like.
Assembling 88 the apparatus may involve a single distributor as an integrated embodiment as described with respect to FIG. 2, or assembly of a reactor, with a feed line 18, connected to a distributor 12. Likewise, assembling 88 may also include the disposition of reactants within various locations within a reactor 20, distributor 12, or the like as discussed hereinabove.
Deploying 90 the distributor may involve opening up a package provided during assembly 88 of the apparatus 10. For example, assembling 88 may also include packaging. Accordingly, deploying 90 may involve opening packages, unsealing components, and otherwise rendering the apparatus 10 ready for use. Likewise, deploying 90 the distributor 12 may involve positioning the distributor 12 with respect to a user, including, for example, adhering the distributor 12 to the skin of a user proximate the nostrils for inhaling the nitric oxide provided by the distributor 12.
Activating 92 the reactants in the reactor 20 may involve, either adding a liquid, mixing the reactant components together, dispersing individual reactants in respective solutes to provide solutions for mixing, adding a liquid transport carrier to dry ingredients in order to initiate exchange between reactants, a combination thereof, or the like.
Likewise, activation 92 of the reactants may also involve opening valves, opening seals, rupturing or otherwise compromising seals as described hereinabove, or otherwise moving or manipulating reactants with or without carriers in order to place them in chemical contact with one another.
In certain embodiments, nitric oxide may be separated 94 from the reactants themselves. For example, the concept of a molecular sieve 60 was introduced hereinabove as one mechanism to separate 94 nitric oxide form other reactants and from other species of nitrogen compounds. In other embodiments, pumps, vacuum devices, or the like may also tend to separate 94 nitric oxide. Accordingly, in certain embodiments, a suitably sized pump may actually be connected to the reactor 20 in order to draw nitric oxide away from other species of reactants or reacted outputs.
Conducting 96 therapy using nitric oxide may involve a number of steps associated with delivery and monitoring of nitric oxide through the distributor 12. For example, in certain embodiments, conducting 96 therapy may involve activating a reactor 20 or the contents thereof. Likewise, conducting 96 a therapy session may involve proper application of the distributor 12 to the person of the user such as by adhering an adhesive strip 42 to the skin of a user in order to position the output ports 14 in the nostrils of a user for receiving nitric oxide therefrom. It may include assembling the necessary conduit 18 or line 18 with the distributor 12 to send nitric oxide from the reactor 20 to the distributor 12, and ultimately to a user.
Monitoring may involve adding gauges or meters, taking samples, or the like in order to verify that the delivery of nitric oxide from the reactor 20 to the distributor 12 does meet the therapeutically designed maximum and minimum threshold requirements specified by a medical professional.
Ultimately, after the expiration of an appropriate time specified, or the exhaustion of a content of a reactor 20, a therapy session may be considered completed. Accordingly, the apparatus 10 may be removed 98 from use, discarded, or the like. Accordingly, the removal or discarding 98 of the apparatus 10 may be by parts, or by the entirety. For example, the distributor 12, if it does not include an integrated reactor therewithin, may simply act as a manifold and be reused with a new reactor 20.
It is contemplated that the reactor 20 may typically be a single dose reactor but need not be limited to such. Multiple-dose or reusable reactors may also be used. For example, the reactor 20 may actually contain a cartridge placed within the wall 56. The internal structure of the cartridge may be ruptured in the appropriate seal locations, such as the seals 64, 70 by a mechanism associated with the main containment vessel or wall 56, and thus activated. Accordingly, the reactor 20 may be reused by simply replacing the cartridge of materials containing the reactant volumes 66, 68.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative, and not restrictive. The scope of the invention is, therefore, indicated by the appended claims, rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
"
sheesh..yah been a while since heard anything from these guys..would be nice if they starting ramping up some press sheesh
i've tried calling and emailing the company several times.. they won't respond to me
i did speak with the receptionist briefly but couldn't get much out of her
Hey DB!Looks that way!
interesting? is this really new as it appears to be??->
http://www.sltrib.com/sltrib/money/56273575-79/patent-invented-assigned-lake.html.csp
"
Nitric oxide reactor and distributor apparatus and method, patent No. 8,434,475, invented by Randy J. Miller of Orem, and Christie M. Jones of Chula Vista, Calif., assigned to Genosys, Inc. of Provo.
"
.
.
.
"
Everett Robinson, who is an attorney registered with the U.S. Patent and Trademark Office, compiles this list weekly for the Salt Lake Tribune. Robinson can be reached at 801-649-5858. For more patents, see the Money page at sltrib.com, go to Sections on the left-hand side and click Patents.
"
Dale Fillmore's linked in says he's ceo of GeNOsys International Inc...
searched and see this started website that never got too far
http://genosysinternational.wordpress.com/
no doubt..would be fitting
i hope something is coming after seeing their form 4's .... we'll see
g/l
nice bro!
we due here imo!))outta nowhere!
some ok action today 05 last 06s were hit nicely..lets see what haps! still think if they announce FDA approval for their med device we know what can hap to this stock!)fings crossed!!
GM DB and all!)
im back as mod with ya bud!)hate how ihub takes a person down if they arent posting for some months lol.Heck not like ive ever lost faith jus wasnt any interest so had it on my backburner.Heres to this gooding put on the frontburner SOON!)im ready..may even have to scoop more hmm
unfortunately we don't know as they didn't put in an explanation ... i'm sure it's either for placement ie: funding OR deferred salaries..etc
either way i'll take it
g/l
now are those form 4s for directors/execs compensation or did they actually buy and pay for those as a loan persay to company?Thanks in advance havent dug that deep into those form 4s yet only glanced at them.Interesting either way imo!
agreed!)
bring it on..all i know been a nice n long wait lol..heres to fruition soon and PR!
i'm guessing something is probably coming ... hence all the insider 'participation' all the sudden
IMO
Good Morning DB!))noticed the form 4s and wakeage last week..heres to this waking BIGLY soon finally...and some blockbuster news would help lol..bring FDA approval!!!!!!!!
I wish I woulda added those .02s a while back, might throw in another bid here but I already have quite a bit.
i was just kidding about the shhhhh part.... but i am trying to raise cash for an add here
shhhh.... trying to sell some things to add here ...g/l
interesting form 4/a filed.. if nothing else shows the skin they have in this game imo
nice.. saw that
nice! g/l to us!!
been in for a few months:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72688598
almost got some more 3s today but missed em
u get any ?
i'm more than ready, level 2 looks like easy over .10 with good news imo
ALPS off ask to .10 now too
GA DB!some action here support and UTage!bring it!!
thanks will do!)
well no more snow here and goin to be in the 60s this weekend and 70s next week so will most definitely enjoy the weather at least lol!)see ya lata!)DF
have a nice weekend DB!)will see what next week brings!)eom
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
205
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
GeNOsys, Inc. Reports Recent Developments and Third Quarter 2008 Financial Results
PROVO, UT, Oct 16, 2008 (MARKET WIRE via COMTEX) -- GeNOsys, Inc. (OTCBB: GNYS), a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems, today announced recent key achievements and financial results for the third quarter and first nine months ended August 31, 2008.
Recent Business Development Milestones
-- Completed the research and development, engineering and construction
of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators. The
Company has been issued a patent on the GeNOx-B and has applied for a
patent on the GeNOx-P.
-- Completed preliminary research and development on the proprietary
tablet medium GeNOx-Tablet. Additionally, a formula for the bulk
manufacture of the tablet medium has been formulated. This formula will be
essential to carry out the business model of the Company as a commercially
viable reoccurring revenue producer of Nitric Oxide Gas Generators.
"The third quarter of fiscal 2008 was another active and productive period for GeNOsys, highlighted by the completion of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators," said Mr. Clark Mower, Chairman of the Board of Directors of GeNOsys. "Independent research has shown that Nitric Oxide gas, an FDA approved drug for use in the treatment of pulmonary hypertension in new-borns, may be an effective agent for the treatment of tuberculosis. Through our technology we are able to generate high purity Nitric Oxide for a significantly reduced cost. Now that we have completed this process, our plan includes a multi-track process of FDA and ISO 13485:2003 approvals in order to monetize our products.
Mr. Mower continued, "GeNOsys has a very large opportunity through the commercialization of our generators. Despite infecting nearly two billion people with the bacteria, which is one-third of the world's population, tuberculosis is "The Forgotten Plague," according to a recent article in Time magazine. The World Health Organization states that no new class of drug has been developed for its treatment in over thirty years. By 2010, the market for anti-tuberculosis drugs is projected to be between $612 and $670 million. The potential market for a new anti-tuberculosis drug is estimated to be between $316 and $345 million according to The Global Alliance for Tuberculosis Drug Development. Additionally, our research has shown that there are several other markets in which our generators have the potential to be used."
Financial results for the three months ended August 31, 2008
During the three-month period ended August 31, 2008, GeNOsys had a net loss of $332,349. This compares to a net loss of $239,738 for the comparable period ended August 31, 2007. Net loss per common share for each of the three month periods was $(.01).
Research and development ("R&D") expenses were $185,129 and $120,163, respectively, for the three-month periods ended August 31, 2008, and 2007, an increase of $64,966. The increase results from non-cash stock-based compensation charges, which were $15,488 higher in the 2008 period, from consulting and advisory board fees, and for additional work on both the nitric oxide generator and the tablet formulation to bring them to finalization. As the work on document preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $147,152 and $122,907, respectively, for the three-month periods ended August 31, 2008 and 2007, an increase of $24,245. The increase results from the non-cash stock-based compensation charge, which was $22,287 higher in 2008 than in the comparable 2007 period. Excluding that charge, general and administrative expenses would have remained flat in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses were incurred in raising the additional capital needed to fund our operations and bring our products to market.
Financial results for the nine months ended August 31, 2008
During the nine-month period ended August 31, 2008, GeNOsys had a net loss of $970,224. This compares to a net loss of $657,293 for the comparable period ended August 31, 2007. Net loss per common share for these periods was $(.02) and $(.01), respectively.
Research and development ("R&D") expenses were $515,832 and $319,086, respectively, for the nine-month periods ended August 31, 2008 and 2007. A significant portion of the $196,746 increase in research and development expenditures resulted from higher non-cash stock-based compensation charges in 2008, which exceeded the 2007 charge by $92,326. Increases were also seen in consulting fees and advisory board fees for additional work on both the nitric oxide generator and the tablet formulation. As the documentation preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $456,656 and $355,396, respectively, for the nine-month periods ended August 31, 2008 and 2007. The increase results from non-cash stock-based compensation charges, which were $132,859 higher in 2008 than 2007. Excluding that charge, general and administrative expenses would have decreased by $31,599 in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses are incurred in raising the additional capital needed to fund operations and bring the products to market.
About GeNOsys, Inc.
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas is one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company's Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
From
Beginning
of
Development
Stage
(June 30,
2005)
For the Three Months For the Nine Months To August
Ended August 31, Ended August 31, 31,
2008 2007 2008 2007 2008
----------- ----------- ----------- ----------- -----------
Revenues $ - $ - $ - $ - $ -
Cost of sales - - - - -
----------- ----------- ----------- ----------- -----------
Gross margin - - - - -
Operating
expenses:
Research and
development 185,129 120,163 515,832 319,086 1,735,288
General and
administra-
tive 147,152 122,907 456,656 355,396 1,733,279
----------- ----------- ----------- ----------- -----------
Total
operating
expenses 332,281 243,070 972,488 674,482 3,468,567
----------- ----------- ----------- ----------- -----------
Net income
(loss) from
operations (332,281) (243,070) (972,488) (674,482) (3,468,567)
----------- ----------- ----------- ----------- -----------
Other income
(expense):
Interest
income 47 3,332 2,379 17,503 82,198
Gain (loss)
on disposal
of asset - - - (414) (414)
Other income
(expense) - - - 100 100
----------- ----------- ----------- ----------- -----------
Total other
income
(expense),
net 47 3,332 2,379 17,189 81,884
----------- ----------- ----------- ----------- -----------
Net income
(loss) before
income Taxes (332,234) (239,738) (970,109) (657,293) (3,386,683)
----------- ----------- ----------- ----------- -----------
Provision
(benefit) for
income Tax 115 - 115 - 415
----------- ----------- ----------- ----------- -----------
Income (loss)
from continuing
operations (332,349) (239,738) (970,224) (657,293) (3,387,098)
Discontinued
operations:
Loss from
discontinued
operations,
net of tax - - - - (2,131)
Gain on
disposal of
discontinued
operations,
net of tax - - - - 71,253
----------- ----------- ----------- ----------- -----------
Net income
(loss) $ (332,349)$ (239,738) $ (970,224)$ (657,293)$(3,317,976)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
continuing
operations $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
discontinued
operations $ - $ - $ - $ - $ -
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted
weighted
average
number of
common shares
outstanding 46,148,787 45,668,031 46,002,850 45,668,031 45,252,720
=========== =========== =========== =========== ===========
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
From
Beginning
of
Development
For the Nine For the Nine Stage (June
Months Ended Months Ended 30, 2005)
August August to August
31, 2008 31, 2007 31, 2008
------------ ------------ ------------
Cash flows from operating
activities:
Net loss $ (970,224) $ (657,293) $ (3,317,976)
Adjustments to reconcile net
loss to net cash used in
operating activities:
Depreciation and amortization 38,954 34,200 97,135
Gain on the disposal of
discontinued Operations - - (71,253)
Loss on disposal of equipment - 414 414
Stock-based compensation 281,616 56,431 420,355
Decrease in cash from
discontinued operations - - (6,020)
Stock issued for services 8,536 - 278,536
Changes in operating assets
and liabilities:
(Increase) Decrease in
prepaid expenses (37,197) 64,956 (40,943)
Increase (Decrease) in
accounts payable 55,048 14,030 68,197
Increase (Decrease) in
related party liabilities (9,340) - 4,000
Increase (Decrease) in
accrued liabilities 195,522 (38,358) 209,729
Increase (Decrease) in tax
payable - - 200
------------ ------------ ------------
Net cash used in
operating activities (437,085) (525,620) (2,357,626)
------------ ------------ ------------
Cash flows from investing
activities:
Purchase of intangible assets (27,543) (33,634) (69,672)
Purchase of equipment (1,021) (18,200) (207,501)
------------ ------------ ------------
Net cash provided by
(used in) investing
Activities (28,564) (51,834) (277,173)
------------ ------------ ------------
Cash flows from financing
activities:
Issuance of common stock for
cash 153,500 - 2,574,604
Proceeds from related party
loans 36,000 - 36,000
Cash from discontinued
operations - - (19,777)
------------ ------------ ------------
Net cash provided by
financing activities 189,500 - 2,590,827
------------ ------------ ------------
Net increase (decrease) in cash (276,149) (577,454) (43,972)
Cash at beginning of the period 280,105 904,715 47,928
------------ ------------ ------------
Cash at end of the period $ 3,956 $ 327,261 $ 3,956
============ ============ ============
Supplemental Disclosure
Information
Cash paid during the year for:
Interest $ - $ - $ 750
Income/franchise taxes - - 200
Stock issued for services 8,536 - 278,536
============ ============ ============
Contact:
Alliance Advisors, LLC
Alan Sheinwald
President
(914) 669-0222
Email Contact
Mark McPartland
Vice President
(910) 686-0455
Email Contact
GeNOsys, Inc.
Michael Dancy
(801) 746-3570
Email Contact
SOURCE: GeNOsys, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |